Pfizer announced positive results from its late stage trials of Xtandi, its potential prostate cancer treatment along with its research partner, Astellas Pharma.
The following information does not take into account your personal objectives, financial situation or needs. You should consider if the relevant investment is appropriate having regard to your own objectives, financial situation and needs.
Xtandi was incorporated into Pfizer’s stable after it acquired Medivation for US$14 billion in 2016. The trials found that when Xtandi is combined with existing prostate cancer therapy for patients whose cancer had not yet spread through the body, it improved survival rates relative to just standard prostate treatments using anti-hormones. In other words, the drug appears to have prevented metastases from developing in the trail patients.
There are currently no FDA-approved treatments for patients with non-metastatic castration-resistant prostate cancer and Xtandi is currently only approved for patients with metastatic disease, in which it generated US$2.3 billion in sales. Therefore, this breakthrough has the potential to expand the use of the Xtandi (along with Johnson & Johnson’s proposed rival drug, Zytiga) and increase the total addressable market size to include all patients with castration-resistant prostate cancer.